Myelofibrosis trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Myelofibrosis. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month4 studies across 3 companies, in the next 180 days.
September 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| KPTI | Karyopharm Therapeutics Inc | A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated MyelofibrosisNCT04562870Percentage of Participants with Spleen Volume Reduction of Greater Than or Equal to (≥) 35 Percent (%) (SVR35) | Phase 2 | Active, not recruiting | Sep 2026 | ≤ 41 d | 2026-07-02 |
October 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| SOBI.ST | Swedish Orphan Biovitrum | A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia MyelofibrosisNCT03165734Spleen volume | Phase 3 | Active, not recruiting | 2026-10-05 | in 46 d | 2026-04-30 |
January 2027 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| SOBI.ST | Swedish Orphan Biovitrum | Pacritinib Effectiveness in Real-world SettingsNCT07774455observational≥50% spleen length reduction | — | Not yet recruiting | 2027-01-27 | in 160 d | 2026-08-19 |
| ABBV | AbbVie | Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With MyelofibrosisNCT04454658Percentage of Participants With Adverse Events | Phase 1 | Active, not recruiting | Jan 2027 | ≤ 164 d | 2025-07-16 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Myelofibrosis
most recently updated first43 studies match.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SOBI.ST | Swedish Orphan Biovitrum | — | Pacritinib Effectiveness in Real-world SettingsNCT07774455observational≥50% spleen length reduction | — | Not yet recruiting | Other: Not applicable- observational study | Myelofibrosis (MF) | 60 | 2026-08-01 | 2027-01-27 | in 160 d | 2026-08-19 |
| IRON | Disc Medicine, Inc | $3.1B | Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and AnemiaNCT05320198Safety and Tolerability of DISC-0974 (Phase 1b only) | Phase 1/2 | Recruiting | Drug: DISC-0974 | Myelofibrosis; Anemia, Anemia, Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera, Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Myelodysplastic Syndromes | 150 | 2022-06-06 | May 2027 | ≤ 284 d | 2026-08-12 |
| PRLD | Prelude Therapeutics | $459M | A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative NeoplasmsNCT07469891Dose limiting toxicity (DLT) of PRT12396 | Phase 1 | Recruiting | Drug: PRT12396 | Polycythemia Vera (PV), Myelofibrosis (MF), Myeloproliferative Neoplasms (MPNs), Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, Primary Myelofibrosis (PMF) | 100 | 2026-04-29 | Apr 2028 | ≤ 619 d | 2026-07-31 |
| GERN | Geron Corporation | $983M | A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor TreatmentNCT04576156Overall survival (OS) | Phase 3 | Active, not recruiting | Drug: Imetelstat, Best Available Therapy (BAT) | Myelofibrosis | 327 | 2021-04-12 | 2028-06-30 | in 680 d | 2026-07-08 |
| KPTI | Karyopharm Therapeutics Inc | $44M | A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated MyelofibrosisNCT04562870Percentage of Participants with Spleen Volume Reduction of Greater Than or Equal to (≥) 35 Percent (%) (SVR35) | Phase 2 | Active, not recruiting | Drug: Selinexor · Other: Physician's Choice Treatment | Myelofibrosis | 112 | 2021-03-17 | Sep 2026 | ≤ 41 d | 2026-07-02 |
| INCY | Incyte Corporation | $24.7B | A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of ItacitinibNCT04640025Treatment Emergent Adverse Events (TEAE's) | Phase 2 | Terminatedsponsor's stated reason: The decision to close the study was made due to the expiration of remaining drug supply. | Drug: itacitinib | Myelofibrosis, Postlung Transplant (Bronchiolitis Obliterans), Chronic Graft Versus Host Disease | 18 | 2021-03-10 | 2026-05-11actual | — | 2026-06-26 |
| INCY | Incyte Corporation | $24.7B | INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative DisordersNCT04455841results2026-05-12Number of Participants With Any Treatment-emergent Adverse Event (TEAE) and Any Treatment-emergent Serious Adverse Event (SAE) | Phase 1/2 | Active, not recruiting | Drug: INCB000928, ruxolitinib | Anemia, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis | 84 | 2021-03-19 | 2025-04-01actual | — | 2026-05-14 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)NCT04817007Incidence of adverse events (AEs) | Phase 1/2 | Active, not recruiting | Drug: BMS-986158, Ruxolitinib, Fedratinib | Myelofibrosis | 216 | 2021-03-22 | 2028-08-31 | in 742 d | 2026-05-08 |
| SOBI.ST | Swedish Orphan Biovitrum | — | A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia MyelofibrosisNCT03165734Spleen volume | Phase 3 | Active, not recruiting | Drug: Pacritinib, Physician's Choice medications | Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis | 407 | 2017-06-26 | 2026-10-05 | in 46 d | 2026-04-30 |
| KPTI | Karyopharm Therapeutics Inc | $44M | Study of Selinexor in Combination With Ruxolitinib in MyelofibrosisNCT04562389Phase 3: Proportion of Participants with Spleen Volume Reduction (SVR) of Greater than or Equal to (>=) 35 Percent (%) (SVR35) at Week 24 Measured by the Magnetic Resonance Imaging (MRI) or Computed Tomography (CT) Scan | Phase 3 | Active, not recruiting | Drug: Selinexor, Selinexor, Ruxolitinib · Other: Placebo | Myelofibrosis | 353 | 2021-03-11 | 2026-02-20actual | — | 2026-04-09 |
| INCY | Incyte Corporation | $24.7B | Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid NeoplasmsNCT04279847Number of treatment-emergent adverse events | Phase 1 | Active, not recruiting | Drug: INCB057643, Ruxolitinib | Myelofibrosis, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome, Myeloproliferative Neoplasm, Relapsed or Refractory Primary Myelofibrosis, Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis), ET (Essential Thrombocythemia) | 140 | 2021-02-23 | 2027-04-30 | in 253 d | 2026-04-01 |
| ABBV | AbbVie | $457.5B | Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With MyelofibrosisNCT04472598results2026-03-23Percentage of Participants With ≥ 35% Reduction From Baseline in Spleen Volume at Week 24 (SVR35W24) | Phase 3 | Completed | Drug: Placebo for Navitoclax, Ruxolitinib, Navitoclax | Myelofibrosis (MF) | 252 | 2020-09-29 | 2023-04-13actual | — | 2026-03-23 |
| KPTI | Karyopharm Therapeutics Inc | $44M | Karyopharm Expanded Access Program for SelinexorNCT07215832expanded access | — | Available | Drug: selinexor | Multiple Myeloma, Diffuse Large B-Cell Lymphoma (DLBCL), Sarcoma, Neuroglioblastoma, Peripheral T-cell Lymphoma, Endometrial Cancer, Myelofibrosis, Other | — | — | — | — | 2026-03-02 |
| KPTI | Karyopharm Therapeutics Inc | $44M | A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate ThrombocytopeniaNCT05980806Proportion of Participants with Spleen Volume Reduction ≥35% (SVR35) at Week 24 | Phase 2 | Recruiting | Drug: Selinexor 60 mg, Selinexor 40 mg, Ruxolitinib, Pacritinib, Momelotinib | Myelofibrosis, Moderate Thrombocytopenia, Mild Thrombocytopenia | 58 | 2024-04-22 | Jun 2027 | ≤ 314 d | 2026-02-12 |
| ABBV | AbbVie | $457.5B | A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With MyelofibrosisNCT03222609results2025-03-12Percentage of Participants With ≥ 35% Reduction From Baseline in Spleen Volume at Week 24 | Phase 2 | Completed | Drug: Ruxolitinib, Navitoclax | Myelofibrosis (MF) | 191 | 2017-10-31 | 2022-03-28actual | — | 2026-01-20 |
| ABBV | AbbVie | $457.5B | Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory MyelofibrosisNCT04468984Arms A and B: Percentage of Participants who achieve Spleen Volume Reduction of at least 35% at Week 24 (SVR35W24) | Phase 3 | Active, not recruiting | Drug: Navitoclax, Ruxolitinib, Best Available Therapy (BAT) | Myelofibrosis (MF) | 330 | 2020-08-31 | 2025-01-29actual | — | 2026-01-09 |
| GERN | Geron Corporation | $983M | A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With MyelofibrosisNCT05371964Part 1: Incidence, Type, and Severity of Adverse Events, Including Dose-limiting Toxicity (DLT) During the DLT Observation Period and/or Study Treatment | Phase 1 | Recruiting | Drug: Imetelstat sodium, Ruxolitinib | Myelofibrosis | 36 | 2022-05-04 | Feb 2027 | ≤ 192 d | 2026-01-06 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)NCT04446650Maximum Tolerated Dose (MTD) | Phase 1/2 | Active, not recruiting | Drug: Fedratinib | Primary Myelofibrosis | 31 | 2020-10-12 | 2023-10-05actual | — | 2025-10-21 |
| INCY | Incyte Corporation | $24.7B | To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)NCT04551066results2024-10-04Percentage of Participants Achieving ≥35% Reduction in Spleen Volume From Baseline to Week 24 as Measured by Magnetic Resonance Imaging [MRI] (or Computed Tomography [CT] Scan in Applicable Participants) | Phase 3 | Terminatedsponsor's stated reason: The study was terminated due to futility. | Drug: parsaclisib, ruxolitinib, placebo | Myelofibrosis, Primary Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis | 252 | 2021-05-24 | 2023-08-03actual | — | 2025-10-21 |
| INCY | Incyte Corporation | $24.7B | To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)NCT04551053results2024-08-23Percentage of Participants Achieving ≥25% Reduction in Spleen Volume From Baseline to Week 24 as Measured by Magnetic Resonance Imaging (MRI) (or Computed Tomography [CT] Scan in Applicable Participants) | Phase 3 | Terminatedsponsor's stated reason: The study was terminated due to futility. | Drug: parsaclisib, ruxolitinib, placebo | Myelofibrosis, Primary Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis | 177 | 2021-05-26 | 2023-08-16actual | — | 2025-10-02 |
| INCY | Incyte Corporation | $24.7B | To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)NCT04629508results2024-09-19Part 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | Phase 2 | Completed | Drug: itacitinib | Myelofibrosis, Polycythemia Vera, Thrombocythemia | 4 | 2021-07-12 | 2023-08-24actual | — | 2025-09-02 |
| INCY | Incyte Corporation | $24.7B | Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)NCT01317875results2022-03-09Number of Participants With Dose Limiting Toxicities | Phase 1 | Completed | Drug: Ruxolitinib | Myelofibrosis | 69 | 2011-03-31 | 2019-12-31actual | — | 2025-08-22 |
| ABBV | AbbVie | $457.5B | Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With MyelofibrosisNCT04454658Percentage of Participants With Adverse Events | Phase 1 | Active, not recruiting | Drug: ABBV-744, Navitoclax, Ruxolitinib | Myelofibrosis (MF) | 21 | 2020-11-11 | Jan 2027 | ≤ 164 d | 2025-07-16 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Assess Real-World Patient-Reported Outcomes With Fedratinib for Myelofibrosis Post-RuxolitinibNCT05665192observationalPercentage change in Total Symptom Score (TSS) assessed by Myelofibrosis Symptom Assessment Form (MFSAF) | — | Completed | — | Myelofibrosis | 150 | 2021-08-02 | 2023-07-24actual | — | 2025-04-08 |
| BMY | Bristol-Myers Squibb | $134.9B | A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With MyelofibrosisNCT00724334Safety (i.e. adverse events, effects on laboratory parameters, vital signs and ECGs) and tolerability | Phase 1/2 | Completed | Drug: SAR302503 (TG101348) | Myelofibrosis | 42 | Jul 2008 | May 2014actual | — | 2025-03-05 |
| BMY | Bristol-Myers Squibb | $134.9B | Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With SplenomegalyNCT01692366Response Rate (RR), defined as the proportion of subjects who have a ≥35% reduction as measured by MRI (or CT scan in subjects with contraindications for MRI). - Time Frame: | Phase 2 | Completed | Drug: SAR302503 | Myelofibrosis | 8 | Nov 2012 | Mar 2014actual | — | 2025-03-05 |
| BMY | Bristol-Myers Squibb | $134.9B | A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With MyelofibrosisNCT06073847observationalNumber of participants with adverse events | — | Recruiting | Drug: Fedratinib | Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis | 137 | 2023-06-13 | 2027-12-20 | in 487 d | 2024-11-06 |
| ABBV | AbbVie | $457.5B | Expanded Access to NavitoclaxNCT03592576expanded access | — | No longer available | Drug: Navitoclax, Venetoclax | Myelofibrosis, Acute Lymphocytic Leukemia (ALL), Lymphoblastic Lymphoma | — | — | — | — | 2024-05-06 |
| ACTU | Actuate Therapeutics Inc. | $25M | Actuate 1901: 9-ING-41 in MyelofibrosisNCT04218071Response rate | Phase 2 | Completed | Drug: Ruxolitinib, 9-ING-41 | Myelofibrosis | 17 | 2020-08-20 | 2022-10-13actual | — | 2024-02-07 |
| ABBV | AbbVie | $457.5B | A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart ReviewNCT05444972observationalTime from Diagnosis of Myelofibrosis (MF) to Initial Treatment | — | Completed | — | Myelofibrosis | 998 | 2022-08-23 | 2023-11-14actual | — | 2023-12-11 |
| ABBV | AbbVie | $457.5B | Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With MyelofibrosisNCT04480086Percentage of Participants With Adverse Events | Phase 1 | Terminatedsponsor's stated reason: Strategic considerations | Drug: Mivebresib, Navitoclax, Ruxolitinib | Myelofibrosis (MF) | 1 | 2021-03-17 | 2023-07-28actual | — | 2023-08-29 |
| AAPG | Ascentage Pharma Group Inc. | — | A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial TherapyNCT04354727Dose-limiting toxicity (DLT) rate at each dose level | Phase 1/2 | Withdrawnsponsor's stated reason: Sponsor decision | Drug: APG-1252, Ruxolitinib | Myelofibrosis | 0 | 2020-12-15 | 2022-12-15 | — | 2022-07-12 |
| GERN | Geron Corporation | $983M | Imetelstat Sodium in Treating Participants With Primary or Secondary MyelofibrosisNCT01731951results2021-09-21MF Participants: Percentage of Participants With Overall Response (OR) - (Clinical Improvement[CI] or Partial Remission[PR] or Complete Remission[CR]) Per International Working Group - Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) Criteria | Phase 2 | Completed | Drug: Imetelstat | Primary Myelofibrosis, Secondary Myelofibrosis, Myeloid Malignancies | 80 | 2012-10-29 | 2018-05-24actual | — | 2021-09-21 |
| GERN | Geron Corporation | $983M | Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) InhibitorNCT02426086results2021-09-14Percentage of Participants With Spleen Response | Phase 2 | Completed | Drug: Imetelstat 4.7 mg/kg, Imetelstat 9.4 mg/kg | Myelofibrosis | 107 | 2015-08-28 | 2018-04-26actual | — | 2021-09-14 |
| GILD | Gilead Sciences | $177.9B | Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed DiseaseNCT02436135results2020-08-14Percentage of Participants Experiencing Any Treatment Emergent Adverse Events Within 28 Days of Idelalisib Exposure | Phase 1 | Terminated | Drug: Idelalisib, Ruxolitinib | Myelofibrosis | 10 | 2015-06-05 | 2017-11-20actual | — | 2020-09-16 |
| GILD | Gilead Sciences | $177.9B | Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia MyelofibrosisNCT01369498results2020-07-01Rate of Clinical Response as Defined by the Percentage of Participants With Reduction at Week 24 From Baseline in the Bone Marrow Fibrosis Score | Phase 2 | Completed | Drug: Simtuzumab, Ruxolitinib | Myelofibrosis | 54 | 2011-06-30 | 2014-06-05actual | — | 2020-07-01 |
| INCY | Incyte Corporation | $24.7B | Alternative Dosing Strategy of Ruxolitinib in Patients With MyelofibrosisNCT01445769results2014-09-19Mean Percentage Change From Baseline in Spleen Volume at Week 24 | Phase 2 | Completed | Drug: Ruxolitinib | Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis | 45 | Sep 2011 | Mar 2013actual | — | 2019-03-27 |
| LLY | Eli Lilly and Company | $1.15T | A Study in Myeloproliferative DisordersNCT01134120Determination of a recommended Phase 2 dosing regimen | Phase 1 | Completed | Drug: LY2784544 | Myeloproliferative Disorders, Thrombocythemia, Essential, Polycythemia Vera, Primary Myelofibrosis | 80 | Apr 2010 | Apr 2014actual | — | 2018-04-17 |
| INCY | Incyte Corporation | $24.7B | Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia MyelofibrosisNCT00509899results2012-08-02Number of Participants With Adverse Events (AEs) | Phase 1/2 | Completed | Drug: Ruxolitinib | Myelofibrosis, Polycythemia Vera, Thrombocytosis | 154 | Jun 2007 | Dec 2007actual | — | 2018-03-12 |
| AZN | AstraZeneca | — | Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative DiseasesNCT00910728results2017-04-24Pharmacokinetic Parameters Following Single Dosing: AUC0-12 | Phase 1 | Completed | Drug: AZD1480 | Primary Myelofibrosis (PMF), Post-Polycythaemia Vera, Essential Thrombocythaemia Myelofibrosis | 65 | May 2009 | Mar 2012actual | — | 2017-04-24 |
| LLY | Eli Lilly and Company | $1.15T | Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative NeoplasmsNCT01520220Number of participants with LY2784544 dose limiting toxicities (DLT) | Phase 1 | Completed | Drug: LY2784544 | Myeloproliferative Neoplasms of, Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis | 100 | 2012-06-11 | 2015-06-26actual | — | 2017-04-12 |
| INCY | Incyte Corporation | $24.7B | Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis PatientsNCT01340651results2013-09-25Percentage of Participants With at Least 1 Adverse Event From Baseline Through Week 16 | Phase 2 | Completed | Drug: Ruxolitinib | Myelofibrosis | 41 | Mar 2011 | Jul 2012actual | — | 2014-03-10 |
| EXEL | Exelixis | $13.2B | A Safety Study of XL019 in Adults With MyelofibrosisNCT00522574To evaluate the safety, tolerability, maximum tolerated dose, and dose-limiting toxicities of XL019 as a single agent when orally administered in subjects with PMF, post-PV MF, or post-ET MF. | Phase 1 | Terminatedsponsor's stated reason: Due to emerging safety data | Drug: XL019 | Myeloproliferative Disorders, Myelofibrosis, Polycythemia Vera, Thrombocythemia, Essential | 100 | Aug 2007 | — | — | 2011-04-05 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Myelofibrosis is matched — 8 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Myelofibrosis
- Primary Myelofibrosis
- Myelofibrosis (MF)
- Post-essential Thrombocythemia Myelofibrosis
- Post-polycythemia Vera Myelofibrosis
- Post Essential Thrombocythemia Myelofibrosis
- Post Polycythemia Vera Myelofibrosis
- Primary Myelofibrosis (PMF)
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Myelofibrosis” (a text search, wider than this page)